In:
Journal of Diabetes Science and Technology, SAGE Publications, Vol. 16, No. 5 ( 2022-09), p. 1167-1173
Abstract:
CeQur Simplicity™ (CeQur, Marlborough, MA) is a 3-day insulin delivery patch designed to meet mealtime insulin requirements. A recently reported 48-week, randomized, multicenter, interventional trial compared efficacy, safety and self-reported outcomes in 278 adults with type 2 diabetes (T2D) on basal insulin therapy who initiated and managed mealtime insulin therapy with a patch pump versus insulin pen. We assessed changes in key glycemic metrics among a subset of patients who wore a continuous glucose monitoring (CGM) device. Methods: Study participants (patch, n = 49; pen, n = 48) wore a CGM device in masked setting during the baseline period and prior to week 24. Glycemic control was assessed using international consensus guidelines for percentage of Time In Range (%TIR: 〉 70% at 70-180 mg/dL), Time Below Range (%TBR: 〈 4% at 〈 70 mg/dL; 〈 1% at 〈 54 mg/dL), and Time Above Range (%TAR: 〈 25% at 〉 180 mg/dL; 〈 5% at 〉 250 mg/dL). Results: Both the patch and pen groups achieved recommended targets in %TIR (74.1% ± 18.7%, 75.2 ± 16.1%, respectively) and marked reductions in %TAR 〉 180 mg/dL (21.1% ± 19.9%, 19.7% ± 17.5%, respectively) but with increased %TBR 〈 70 mg/dL (4.7% ± 5.2%, 5.1 ± 5.8, respectively), all P 〈 .0001. No significant between-group differences in glycemic improvements or adverse events were observed. Conclusions: CGM confirmed that the patch or pen can be used to safely initiate and optimize basal-bolus therapy using a simple insulin adjustment algorithm with SMBG. Preference data suggest that use of the patch vs pen may enhance treatment adherence.
Type of Medium:
Online Resource
ISSN:
1932-2968
,
1932-2968
DOI:
10.1177/19322968211016513
Language:
English
Publisher:
SAGE Publications
Publication Date:
2022
detail.hit.zdb_id:
2467312-2
Permalink
